IP Library Granted Patent US 7,723,102
Granted Patent B2
US 7,723,102 · App. 09/956,576 · Granted May 25, 2010

Enhanced transfection system

Assignee: Bayer Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,723,102
App. No.
09/956,576
Granted
May 25, 2010
Kind
B2
Abstract

A mammalian cell gene expression vector system comprising (a) an episomal maintenance system (b), a strong promoter/enhancer, (c) a protein transactivation system and (d) DNA coding for a heterologous protein. The episomal maintenance and protein transactivation systems can include sub-elements located on the same or different plasmids within the cell expression system.

Claims (31)

1. A composition comprising a plasmid, the plasmid comprising:

a. an oriP element;

b. a first nucleic acid sequence encoding EBNA 1 operably linked to a promoter;

c. a second nucleic acid sequence encoding TAT operably linked to a promoter;

d. a TAR element; and

e. a third nucleic acid sequence encoding a heterologous protein operably linked to a first CMV promoter/enhancer.

2. The composition of claim 1 , further comprising a nucleic acid sequence encoding BMLF1 operably linked to a second CMV promoter/enhancer.

3. The composition of claim 1 , wherein the heterologous protein is selected from the group consisting of IL-4 and IL-2SA.

4. A method for producing a heterologous protein from a mammalian host cell, comprising the steps of:

(a) transforming the mammalian host cell with the composition of claim 1 ;

(b) expanding the host cell of step (a) in culture; and

(c) isolating the heterologous protein from the culture of step (b).

5. A composition comprising a first plasmid and a second plasmid, wherein the first plasmid comprises an oriP element, a first nucleic acid sequence encoding EBNA1 operably linked to a promoter, and a second nucleic acid sequence encoding TAT operably linked to a promoter, and the second plasmid comprises an oriP element, a TAR element, and a nucleic acid sequence encoding a heterologous protein operably linked to a CMV promoter/enhancer.

6. The composition of claim 5 wherein the first plasmid further comprises a nucleic acid sequence encoding BMLF1 operably linked to a promoter.

7. The composition of claim 5 wherein the heterologous protein is selected from the group consisting of IL-4 and IL-2SA.

8. A method for producing a heterologous protein from a mammalian host cell, comprising the steps of:

(a) transforming the mammalian host cell with the composition of claim 5 ;

(b) expanding the host cell of step (a) in culture; and

(c) isolating the heterologous protein from the culture of step (b).

9. A mammalian cell line transformed with a composition comprising a plasmid, the plasmid comprising:

a. an oriP element;

b. a first nucleic acid sequence encoding EBNA 1 operably linked to a promoter;

c. a second nucleic acid sequence encoding TAT operably linked to a promoter;

d. a TAR element; and

e. a third nucleic acid sequence encoding a heterologous protein operably linked to a first CMV promoter/enhancer.

10. A mammalian cell line transformed with a composition, the composition comprising a first plasmid and a second plasmid, wherein the first plasmid comprises an oriP element, a first nucleic acid sequence encoding EBNA1 operably linked to a promoter, and a second nucleic acid sequence encoding TAT operably linked to a promoter, and the second plasmid comprises an oriP element, a TAR element, and a nucleic acid sequence encoding a heterologous protein operably linked to a CMV promoter/enhancer.

11. A mammalian cell line transformed with at least one plasmid, wherein the cell line expresses EBNA1 prior to transformation, the plasmid comprising:

a. an oriP element;

b. a first nucleic acid sequence encoding TAT operably linked to a promoter;

c. a TAR element; and

d. a second nucleic acid sequence encoding a heterologous protein operably linked to a CMV promoter/enhancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2016
From: BAYER CORPORATION
To: BAYER HEALTHCARE LLC
Reel/Frame 038586/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2008
From: CHO, MYUNG-SAM; YEE, HELENA
To: BAYER CORPORATION
Reel/Frame 021051/0192 →
Continuity (2)
Provisional Application 6038622300 · Sep 28, 2000
Related Publication 20030059942A1 · Mar 27, 2003